Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Keith J who wrote (725)	2/21/1998 2:37:00 AM
From: Todd D. Wiener	Respond to of 1432

Keith- Don't forget that the cited post was written 9 months ago. The author was probably bitter that he hadn't owned BTIM during its huge run-up. Todd

To: Keith J who wrote (725)	2/21/1998 4:27:00 PM
From: Stephen How	Read Replies (1) \| Respond to of 1432

revolutionary? Who ever said Hextend was revolutionary? It's sort of like saying New Coke was revolutionary. Surely not Biotime. It is an improvement over current solutions, which everyone knows. I agree. I don't think Biotime has ever made any such strong claims about Hextend. I don't think they've misrepresented the product. I've only seen such superlatives used by David Crossen of Montgomery Securities. He's refered to it as establishing a new paradigm (https://www.siliconinvestor.com/readmsg.aspx?msgid=2991699) and being "the most undervalued stock in the biotech universe". (I guess "Jono" Steinberg also used alot of superlatives, but I think II Online took down their Biotime stuff after the controversy.) Is David Crossen the only analyst covering this stock? Did he really go to Puerto Rico for the anesthesiology conference? Is that unusal? Is Amy Bell also covering BTIM? Steve